Brief: Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
23/07/2026 21:54
BRIEF-Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) July 23 (Reuters) - Abbvie Inc ABBV.N:
GENMAB AND ABBVIE PROVIDE CLARIFICATION ON PHASE 3 EPCORE® DLBCL-1 TRIAL EVALUATING EPCORITAMAB (DUOBODY®-CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
GENMAB: CLARIFY OVERALL SURVIVAL (OS) WAS SOLE U.S. PRIMARY ENDPOINT IN PHASE 3 EPCORE(®) DLBCL-1 TRIAL AND WAS NOT MET
Source text: ID:nBw2yw6H8a
Further company coverage: ABBV.N
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Genmab A/S
See all newsBrief: Genmab Q3 Net Sales Of Darzalex At $4.24 Bln
European shares rise as retreating bond yields and oil prices boost risk appetite
Live Markets: Oil prices can rise even with a new MoU
Live Markets: What the AI capex cycle might mean for European growth
Live Markets: Ignore politics and buy the dip in Spain's Bonos